Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indoco RemediesBOM:532612 -0.25%65 Pretax Margin % is 16.67% as of Jun. 2026, which is 170% above its 10-year median of 6.18. GuruFocus rates BOM:532612 with a GF Score™ of 65/100 and a GF Value™ of ₹341.61 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Indoco Remedies ranks worse than 66.39% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Indoco Remedies Pretax Margin % Related Terms
Indoco Remedies Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Indoco Remedies's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Indoco Remedies's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indoco Remedies Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indoco Remedies's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Indoco Remedies's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indoco Remedies (BOM:532612) has a Pretax Margin % of 16.67% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Indoco Remedies and its competitors. This is 170% above median its historical median of 6.18. According to the industry distribution chart, Indoco Remedies ranks #638 out of 961 companies in the Drug Manufacturers industry, placing it in the top 66.4%.
Is Indoco Remedies' Pretax Margin % too high?
Indoco Remedies' current Pretax Margin % of 16.67% is 170% above median its 10-year median of 6.18. The Drug Manufacturers industry median Pretax Margin % is 7.06. Indoco Remedies' value of 16.67% is 136.1% above this industry median. Based on the distribution chart, Indoco Remedies ranks #638 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Indoco Remedies has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indoco Remedies' Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Indoco Remedies ranks #638 out of 961 companies for Pretax Margin %. This places Indoco Remedies in the lower half of its industry. The industry median Pretax Margin % is 7.06. Indoco Remedies' value of 16.67% is 136.1% above this benchmark. While the company's 10-year median is 6.18 vs. the industry median of 7.06, Indoco Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.06, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indoco Remedies's current Pretax Margin % of 16.67% is 136.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Indoco Remedies and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indoco Remedies's current Pretax Margin % is 16.67%, which is 170% above median its own 10-year median of 6.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indoco Remedies stock overvalued right now?
Based on GuruFocus' analysis, Indoco Remedies (BOM:532612) is currently considered Possible Value Trap. The stock's GF Value™ is ₹341.61, compared to a current price of ₹222.85 — trading 34.8% below its estimated fair value. The current Pretax Margin % is 16.67%, which is 170% above median its 10-year median of 6.18 and 136.1% above the Drug Manufacturers industry median of 7.06. Indoco Remedies' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Indoco Remedies (BOM:532612), the current Pretax Margin % is 16.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indoco Remedies (BOM:532612) Overvalued in 2026?
Based on GuruFocus' analysis, Indoco Remedies stock appears to be undervalued.
The current stock price of ₹222.85 is trading 34.8% below its estimated GF Value™ of ₹341.61.
GuruFocus considers Indoco Remedies to be Possible Value Trap.
Key valuation signals for BOM:532612:
Pretax Margin %: 16.67% (170% above median its 10-year median of 6.18)
GF Value™: ₹341.61 vs. price of ₹222.85 (34.8% below fair value)
Industry Position: 136.1% above the Drug Manufacturers median (#638 of 961)
No single metric tells the full story. See the BOM:532612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indoco Remedies Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company manufactures products for different therapeutic sectors including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional products, Cardiology, Metabolic Disorders, and Primary Care medicines. The only operating segment of the company is Pharmaceutical Products. Geographically, it generates the majority of the revenue from India.
65GF Score
Get the complete analysis for BOM:532612
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532612 has been successfully added to your 
